Skip to main content
. 2017 Jan 27;76(8):1340–1347. doi: 10.1136/annrheumdis-2016-210322

Table 2.

Primary efficacy endpoint results: ASAS20 response rate at week 12

graphic file with name annrheumdis-2016-210322tb02.jpg

***p≤0.001 versus placebo by normal approximation.

†Non-responder imputation was used: ASAS20 value was set to be non-responsive for patients who had no ASAS20 component data.

ASAS, Assessment of SpondyloArthritis International Society.